Metrics for antibody therapeutics development

A wide variety of full-size monoclonal antibodies (mAbs) and therapeutics derived from alternative antibody formats can be produced through genetic and biological engineering techniques. These molecules are now filling the preclinical and clinical pipelines of every major pharmaceutical company and many biotechnology firms. Metrics for the development of antibody therapeutics, including averages for the number of candidates entering clinical study and development phase lengths for mAbs approved in the United States, were derived from analysis of a dataset of over 600 therapeutic mAbs that entered clinical study sponsored, at least in part, by commercial firms. The results presented provide an overview of the field and context for the evaluation of on-going and prospective mAb development programs. The expansion of therapeutic antibody use through supplemental marketing approvals and the increase in the study of therapeutics derived from alternative antibody formats are discussed.

[1]  J. Reichert,et al.  Development trends for human monoclonal antibody therapeutics , 2010, Nature Reviews Drug Discovery.

[2]  Janice M. Reichert,et al.  Monoclonal antibodies in the clinic , 2001, Nature Biotechnology.

[3]  Donald L Drakeman,et al.  The future of monoclonal antibody technology , 2010, mAbs.

[4]  Janice M Reichert,et al.  Development trends for therapeutic antibody fragments , 2009, Nature Biotechnology.

[5]  R. Owens,et al.  Improved tumor targeting with chemically cross-linked recombinant antibody fragments. , 1994, Cancer research.

[6]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[7]  H. de Haard,et al.  Properties, production, and applications of camelid single-domain antibody fragments , 2007, Applied Microbiology and Biotechnology.

[8]  P. Hudson,et al.  Engineered antibodies , 2003, Nature Medicine.

[9]  L. Álvarez-Vallina,et al.  Antibody engineering: facing new challenges in cancer therapy , 2005, Acta Pharmacologica Sinica.

[10]  S. Muyldermans,et al.  Single-domain antibodies as building blocks for novel therapeutics. , 2008, Current opinion in pharmacology.

[11]  Janice M Reichert,et al.  Monoclonal antibodies as innovative therapeutics. , 2008, Current pharmaceutical biotechnology.

[12]  F. Veronese,et al.  The Impact of PEGylation on Biological Therapies , 2012, BioDrugs.

[13]  Joshua P Cohen,et al.  New challenges to medicare beneficiary access to mAbs , 2009, mAbs.

[14]  Janice M Reichert,et al.  Monoclonal antibody successes in the clinic , 2005, Nature Biotechnology.